Epizyme (NASDAQ:EPZM) had its price target raised by analysts at Cowen from $18.00 to $36.00 in a research note issued to investors on Friday, The Fly reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Cowen’s price target points to a potential upside of 58.45% from the company’s current price.
A number of other equities research analysts have also commented on EPZM. Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating and set a $11.00 price target on the stock. in a research report on Monday, October 21st. Leerink Swann lowered Epizyme from an “outperform” rating to a “market perform” rating in a research report on Friday. Svb Leerink lowered Epizyme from an “outperform” rating to a “market perform” rating in a research report on Friday. Citigroup raised their price target on Epizyme from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wedbush raised their price target on Epizyme from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $26.14.
NASDAQ:EPZM traded down $4.00 during mid-day trading on Friday, hitting $22.72. The company had a trading volume of 165,880 shares, compared to its average volume of 1,233,114. Epizyme has a fifty-two week low of $8.84 and a fifty-two week high of $27.82. The business’s fifty day moving average is $22.25 and its two-hundred day moving average is $15.12. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.90 and a current ratio of 10.90. The firm has a market cap of $2.32 billion, a P/E ratio of -14.11 and a beta of 2.68.
Institutional investors have recently made changes to their positions in the stock. Vigilant Capital Management LLC acquired a new stake in Epizyme in the 4th quarter valued at approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Epizyme by 29.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 1,262 shares during the period. United Services Automobile Association purchased a new stake in shares of Epizyme in the second quarter worth $134,000. Perigon Wealth Management LLC purchased a new stake in shares of Epizyme in the fourth quarter worth $201,000. Finally, Man Group plc purchased a new stake in shares of Epizyme in the second quarter worth $222,000. 86.95% of the stock is currently owned by institutional investors and hedge funds.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Further Reading: Neutral Rating
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.